Travere Therapeutics (TVTX) Long-Term Investments (2014 - 2019)
Travere Therapeutics (TVTX) reported Long-Term Investments of $15.0 million for Q2 2019, little changed on a YoY basis from $15.0 million in Q2 2018, and little changed quarter-over-quarter from $15.0 million in Q1 2019.
Travere Therapeutics (TVTX) Long-Term Investments (2014 - 2019) Analysis & Trends
Travere Therapeutics has reported Long-Term Investments for 3 years, with the latest figure at $15.0 million in Q2 2019.
- For the quarter ending Q2 2019, Long-Term Investments changed 0.0% year-over-year to $15.0 million; the trailing twelve-month figure through Jun 2019 stood at $15.0 million (changed 0.0% YoY), and the FY2018 full-year result was $15.0 million, changed N/A from the prior year.
- Long-Term Investments for Q2 2019 stood at $15.0 million, roughly flat from $15.0 million in the prior quarter.
- The five-year high for Long-Term Investments was $15.0 million in Q1 2018, with the low at $15.0 million in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Travere Therapeutics | 5.07 Bn | 4.99 Bn | 102.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 15.00 Mn |
| Mar 31, 2019 | 15.00 Mn |
| Dec 31, 2018 | 15.00 Mn |
| Sep 30, 2018 | 15.00 Mn |
| Jun 30, 2018 | 15.00 Mn |
| Mar 31, 2018 | 15.00 Mn |
| Sep 30, 2014 | 400,000.00 |